Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses credible, patient-friendly resources that people with rheumatic diseases can access when they or their providers are considering a switch to a biosimilar.
Transcript:
What are some credible, patient-friendly resources that people with rheumatic diseases should access when they or their providers are considering a switch to a biosimilar?
I think the good news is that there’s a lot of resources out there right now. I would start with the FDA, they recently put out some new resources—some new educational content with everything right down to some sample social media content which is I think a great step for FDA to be moving into social media. That was encouraging to see.
I would also encourage some of our resources at a site we have, called 50statenetwork.org, where we have some kind of bullet-point-level information about biosimilars. We try and keep it very concise and approachable for advocates in our community.
But we do not have a monopoly on this information at all. [We] absolutely encourage folks to look up other arthritis organizations that they trust and know out there. [We] would also encourage checking out some major medical institutions like the Mayo Clinic or Cleveland Clinic.
And then also looking at the biosimilar manufacturers themselves. There’s [merckclarifiesbiosimilars.com], there’s pfizerbiosimilars.com as well. I think, like anything else out there, it’s important to look at really a diverse range of resources and use that to kind of bring your understanding of the content to another level.
I think what is encouraging is that there are coalitions out there that have begun to form that are kind of collections of a lot of these stakeholders and taking on education as a number one priority. So that’s something that has missed is educational content from 1 source that is a collection of stakeholders. I would recommend the Biosimilars Forum; [it] will hopefully be producing some content soon. That could be a source for some very diverse range of opinion in 1 spot.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.